LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised

What happened: Eli Lilly reported third-quarter 2026 adjusted EPS of $7.48 and revenue of $24.40 billion, both beating Zacks Consensus Estimates, and raised its full-year 2026 revenue guidance. Key numbers: EPS $7.48 vs. $5.38 estimate, a 39.0% beat, up 7% year over year. Revenue $24.40 billion vs. $22.11 billion estimate, up 39%. Why it matters: Mounjaro and Zepbound remained the primary growth engines and both beat consensus, while newer medicines contributed $17.1 billion to quarterly revenue. The company raised its sales outlook for the year on the results. Market: +6.4% today ($1,370.79), +27.3% YTD, 1.0x vol — as of 15:33 UTC Verified: Q3_2026 (Oct 29) EPS $7.48 vs $6.61 est, +13.2% beat; next print ~Jan 28 Coverage: 3 outlets in 24h

Eli Lilly reported third-quarter 2026 adjusted EPS of $7.48 and revenue of $24.40 billion, both beating Zacks Consensus Estimates, and raised its full-year 2026 revenue guidance.

Mounjaro and Zepbound remained the primary growth engines and both beat consensus, while newer medicines contributed $17.1 billion to quarterly revenue. The company raised its sales outlook for the year on the results. Market: +6.4% today ($1,370.79), +27.3% YTD, 1.0x vol — as of 15:33 UTC Verified: Q3_2026 (Oct 29) EPS $7.48 vs $6.61 est, +13.2% beat; next print ~Jan 28